{"success":true,"data":{"pressRelease":{"id":"34366","rtpr_id":"nPRrE2657a","ticker":"MREO","exchange":"NASDAQ","all_tickers":["MREO","NBIX","4BB"],"title":"REG-4basebio Plc: Appointment of Chief Financial Officer and Board Changes","author":"PR Newswire","published_at":"2026-05-14T06:00:19.967Z","article_body":"4basebio PLC\n\n(\"4basebio\" or the \"Company\")\n\nAppointment of Chief Financial Officer and Board Changes\n*                                                                             \n                                                          Richard Bungay\nappointed as CFO, bringing a strong track record in fundraising, M&A and\npartnering for listed and private companies, including two major exits and\nover $400m raised\nCambridge, UK, 14 May 2026                                                    \n                                                                              \n –4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and\nnucleic acids for next-generation therapeutics, announces the appointment of\nRichard Bungay as Chief Financial Officer, with effect from July 2026. Richard\ntakes over the role from David Roth, who stepped down from the Board earlier\nthis year and remained working with the Company over the orderly handover\nperiod.\n\nRichard is an accomplished leader with over 30 years’ senior finance and\nstrategic experience within the pharmaceutical and biotechnology sector,\nleading both public and private companies from research through all clinical\nphases, regulatory approval and commercialisation. He joins 4basebio from\nSitala Bio Limited, a UK-based private biotech where he helped lead a\nstrategic repositioning of the business, working closely with the CEO and\nboard to raise a signficant Series A round and execute an in-licencing deal\nwith Fosun Pharma for up to $670m.\n\nRichard’s prior roles include CEO and CFO at Diurnal Group plc, where he led\nits acquisition by Neurocrine Biosciences, Inc. (Nasdaq: NBIX) in 2022 at a\n147% one-day premium, CEO and CFO at Mereo Biopharma Group plc (NASDAQ: MREO),\nwhere he helped in-license a portfolio from Novartis and subsequently\ncompleted its AIM IPO, and CFO at Verona Pharma (then listed on the London\nStock Exchange, now a subsidiary of Merck & Co) where he helped recapitalise\nthe company.\n\nEarlier in his career Richard was the Director of Corporate Communications and\nStrategic Planning at Celltech Group plc, a London-listed FTSE-100/250 company\nwhere he helped execute its acquisition by UCB for £1.5bn.\n\nRichard is currently a Non-executive Director of                              \n                                                                              \n     Chroma Therapeutics Ltd                                                  \n                                                               . He qualified\nas a Chartered Accountant with Deloitte and has a First Class degree in\nChemistry from Nottingham University.\n\nBoard Changes\n\nFurther to the above, Mr. Alexander Link, Non-executive Director and 2invest\nAG’s Board appointee, and Mr. Alan Malus, Non-executive Director, have\nstepped down from the Board                                                   \n                                                               with effect\nfrom 31 May 2026 due to other professional commitments.                       \n                                                                              \n            Dr. Heikki Lanckriet, Non-executive Director and former CEO of the\nCompany will take over Mr Link’s role as the Board’s appointee of 2invest\nAG. It is the intention that Mr. Cornel Chiriac, representing M&G, will\nreplace Mr. Malus, subject to the completion of due diligence and regulatory\napproval.                                                                     \n                                             The Directors would like to take\nthis opportunity to thank Mr. Link and Mr. Malus for their contributions to\nthe Board during their tenures.\n\nDr Amy Walker, Chief                                                          \n                                                        Executive Officer of\n4basebio, said:                                                               \n                                                                              \n     “Richard has had a long and accomplished career in the industry,\nbringing significant experience with high growth public and private companies;\nwe are thrilled that he has decided to join 4basebio. 4basebio is\ntransitioning into a phase of accelerated commercial growth, and his strategic\nand financial expertise will be invaluable to support us on this journey.\nRichard’s appointment completes the build out of the senior leadership team\nto help us scale our operations to meet the growing need for high quality\nsynthetic DNA products for advanced therapies and personalised medicines.”\n\nRichard Bungay, Chief Financial Officer at 4basebio, added:                   \n                                                                              \n                                                              “I’ve been\nfollowing 4basebio’s progress for several years and have been impressed by\nwhat the team has achieved in such a short time. I look forward to working\nwith Amy and the wider team to support the Company’s continued growth and\nhelp realise the growth potential of this exciting business as it seeks to\nestablish a ledership position in the manufacturing of next-generation\ntherapeutics.”\n\nFor further enquiries, please contact:\n\n 4basebio PLC                                      +44 (0)12 2396 7943  \n Dr Amy Walker, CEO                                                     \n                                                                        \n Cairn Financial Advisers LLP (Nominated Adviser)  +44 (0)20 7213 0880  \n Jo Turner / Sandy Jamieson / Ed Downes                                 \n                                                                        \n Cavendish Capital Markets Limited (Joint Broker)  +44 (0)20 7220 0500  \n Geoff Nash / Nigel Birks                                               \n                                                                        \n RBC Capital Markets (Joint Broker)                +44 (0)20 7653 4000  \n Kathryn Deegan / Matthew Coakes                                        \n                                                                        \n ICR Healthcare (Media and Investor Relations)     +44 (0)203 707 5700  \n Mary-Jane Elliott / Jessica Hodgson                                    \n                                                                        \n\nAbout 4basebio\n\n4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the\nuse of synthetic DNA to enable next-generation therapeutics and vaccines.\nThrough its proprietary enzymatic DNA synthesis platform, 4basebio produces\nGMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,\novercoming the limitations of plasmid-based systems. The company offers\napplication-specific DNA constructs tailored to the diverse needs of gene\ntherapies, genome editing, mRNA production, and DNA vaccines, helping partners\naccelerate proof-of-concept studies and reach clinical milestones more\nefficiently while maintaining the highest standards of safety and quality.\n\nFor more information, visit                                                   \n                                                        4basebio.com          \n                                   (https://www.4basebio.com/)                \n                                             .\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPRrE2657a","title":"REG-4basebio Plc: Appointment of Chief Financial Officer and Board Changes","author":"PR Newswire","ticker":"MREO","created":"2026-05-14T06:00:19.967Z","tickers":["MREO","NBIX","4BB"],"exchange":"NASDAQ","article_body":"4basebio PLC\n\n(\"4basebio\" or the \"Company\")\n\nAppointment of Chief Financial Officer and Board Changes\n*                                                                             \n                                                          Richard Bungay\nappointed as CFO, bringing a strong track record in fundraising, M&A and\npartnering for listed and private companies, including two major exits and\nover $400m raised\nCambridge, UK, 14 May 2026                                                    \n                                                                              \n –4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and\nnucleic acids for next-generation therapeutics, announces the appointment of\nRichard Bungay as Chief Financial Officer, with effect from July 2026. Richard\ntakes over the role from David Roth, who stepped down from the Board earlier\nthis year and remained working with the Company over the orderly handover\nperiod.\n\nRichard is an accomplished leader with over 30 years’ senior finance and\nstrategic experience within the pharmaceutical and biotechnology sector,\nleading both public and private companies from research through all clinical\nphases, regulatory approval and commercialisation. He joins 4basebio from\nSitala Bio Limited, a UK-based private biotech where he helped lead a\nstrategic repositioning of the business, working closely with the CEO and\nboard to raise a signficant Series A round and execute an in-licencing deal\nwith Fosun Pharma for up to $670m.\n\nRichard’s prior roles include CEO and CFO at Diurnal Group plc, where he led\nits acquisition by Neurocrine Biosciences, Inc. (Nasdaq: NBIX) in 2022 at a\n147% one-day premium, CEO and CFO at Mereo Biopharma Group plc (NASDAQ: MREO),\nwhere he helped in-license a portfolio from Novartis and subsequently\ncompleted its AIM IPO, and CFO at Verona Pharma (then listed on the London\nStock Exchange, now a subsidiary of Merck & Co) where he helped recapitalise\nthe company.\n\nEarlier in his career Richard was the Director of Corporate Communications and\nStrategic Planning at Celltech Group plc, a London-listed FTSE-100/250 company\nwhere he helped execute its acquisition by UCB for £1.5bn.\n\nRichard is currently a Non-executive Director of                              \n                                                                              \n     Chroma Therapeutics Ltd                                                  \n                                                               . He qualified\nas a Chartered Accountant with Deloitte and has a First Class degree in\nChemistry from Nottingham University.\n\nBoard Changes\n\nFurther to the above, Mr. Alexander Link, Non-executive Director and 2invest\nAG’s Board appointee, and Mr. Alan Malus, Non-executive Director, have\nstepped down from the Board                                                   \n                                                               with effect\nfrom 31 May 2026 due to other professional commitments.                       \n                                                                              \n            Dr. Heikki Lanckriet, Non-executive Director and former CEO of the\nCompany will take over Mr Link’s role as the Board’s appointee of 2invest\nAG. It is the intention that Mr. Cornel Chiriac, representing M&G, will\nreplace Mr. Malus, subject to the completion of due diligence and regulatory\napproval.                                                                     \n                                             The Directors would like to take\nthis opportunity to thank Mr. Link and Mr. Malus for their contributions to\nthe Board during their tenures.\n\nDr Amy Walker, Chief                                                          \n                                                        Executive Officer of\n4basebio, said:                                                               \n                                                                              \n     “Richard has had a long and accomplished career in the industry,\nbringing significant experience with high growth public and private companies;\nwe are thrilled that he has decided to join 4basebio. 4basebio is\ntransitioning into a phase of accelerated commercial growth, and his strategic\nand financial expertise will be invaluable to support us on this journey.\nRichard’s appointment completes the build out of the senior leadership team\nto help us scale our operations to meet the growing need for high quality\nsynthetic DNA products for advanced therapies and personalised medicines.”\n\nRichard Bungay, Chief Financial Officer at 4basebio, added:                   \n                                                                              \n                                                              “I’ve been\nfollowing 4basebio’s progress for several years and have been impressed by\nwhat the team has achieved in such a short time. I look forward to working\nwith Amy and the wider team to support the Company’s continued growth and\nhelp realise the growth potential of this exciting business as it seeks to\nestablish a ledership position in the manufacturing of next-generation\ntherapeutics.”\n\nFor further enquiries, please contact:\n\n 4basebio PLC                                      +44 (0)12 2396 7943  \n Dr Amy Walker, CEO                                                     \n                                                                        \n Cairn Financial Advisers LLP (Nominated Adviser)  +44 (0)20 7213 0880  \n Jo Turner / Sandy Jamieson / Ed Downes                                 \n                                                                        \n Cavendish Capital Markets Limited (Joint Broker)  +44 (0)20 7220 0500  \n Geoff Nash / Nigel Birks                                               \n                                                                        \n RBC Capital Markets (Joint Broker)                +44 (0)20 7653 4000  \n Kathryn Deegan / Matthew Coakes                                        \n                                                                        \n ICR Healthcare (Media and Investor Relations)     +44 (0)203 707 5700  \n Mary-Jane Elliott / Jessica Hodgson                                    \n                                                                        \n\nAbout 4basebio\n\n4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the\nuse of synthetic DNA to enable next-generation therapeutics and vaccines.\nThrough its proprietary enzymatic DNA synthesis platform, 4basebio produces\nGMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,\novercoming the limitations of plasmid-based systems. The company offers\napplication-specific DNA constructs tailored to the diverse needs of gene\ntherapies, genome editing, mRNA production, and DNA vaccines, helping partners\naccelerate proof-of-concept studies and reach clinical milestones more\nefficiently while maintaining the highest standards of safety and quality.\n\nFor more information, visit                                                   \n                                                        4basebio.com          \n                                   (https://www.4basebio.com/)                \n                                             .\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-14T06:00:20.039704783Z","server_sent_at_ms":1778738420039},"received_at":"2026-05-14T06:00:20.092Z","source_url":null},"analysis":{"id":"24329","press_release_id":"34366","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"4basebio has appointed Richard Bungay as Chief Financial Officer, effective July 2026. Richard brings over 30 years of senior finance and strategic experience, including leading significant fundraising and M&A activities.\n\nNon-executive Directors Alexander Link and Alan Malus have stepped down from the Board due to other professional commitments, effective May 31, 2026. Dr. Heikki Lanckriet will take over Mr. Link’s role, and Mr. Cornel Chiriac is expected to replace Mr. Malus, pending due diligence and regulatory approval.\n\nCEO Amy Walker expressed enthusiasm about Richard’s appointment, noting his strategic and financial expertise will be invaluable as the company transitions into a phase of accelerated commercial growth.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"4basebio strengthens leadership with new CFO and board changes, signaling strategic growth."},"keyFigures":{"customDimensions":{"funding_raised":"$400m","in_licensing_deal_value":"$670m"}},"quotedText":"Richard has had a long and accomplished career in the industry, bringing significant experience with high growth public and private companies; we are thrilled that he has decided to join 4basebio.","namedEntities":{"people":[{"name":"Richard Bungay","role":"CFO"},{"name":"David Roth","role":"former CFO"},{"name":"Alexander Link","role":"Non-executive Director"},{"name":"Alan Malus","role":"Non-executive Director"},{"name":"Heikki Lanckriet","role":"Non-executive Director"},{"name":"Cornel Chiriac","role":"future Non-executive Director"},{"name":"Amy Walker","role":"CEO"}],"products":[],"companies":[{"name":"4basebio PLC","ticker":"MREO"},{"name":"Sitala Bio Limited","relationship":"former employer"},{"name":"Fosun Pharma","relationship":"partner"},{"name":"Diurnal Group plc","relationship":"former employer"},{"name":"Neurocrine Biosciences, Inc.","ticker":"NBIX","relationship":"acquirer"},{"name":"Mereo Biopharma Group plc","ticker":"MREO","relationship":"former employer"},{"name":"Novartis","relationship":"partner"},{"name":"Verona Pharma","relationship":"former employer"},{"name":"Merck & Co","relationship":"acquirer"},{"name":"Celltech Group plc","relationship":"former employer"},{"name":"UCB","relationship":"acquirer"},{"name":"2invest AG","relationship":"shareholder"},{"name":"M&G","relationship":"shareholder"},{"name":"Cairn Financial Advisers LLP","relationship":"Nominated Adviser"},{"name":"Cavendish Capital Markets Limited","relationship":"Joint Broker"},{"name":"RBC Capital Markets","relationship":"Joint Broker"},{"name":"ICR Healthcare","relationship":"Media and Investor Relations"}],"dollarAmounts":[{"amount":"$400m","context":"funding raised by Richard Bungay at Diurnal Group plc"},{"amount":"$670m","context":"in-licensing deal value with Fosun Pharma at Sitala Bio Limited"}]},"materialImpact":{"score":3,"reasoning":"Appointment of a new CFO with a strong track record and significant board changes, which can signal a new strategic direction and improved governance."},"tickerRelevance":{"others":[{"ticker":"NBIX","relevance":"acquirer of Diurnal Group plc"},{"ticker":"4BB","relevance":"mentioned"}],"primary":"MREO"},"globalImportance":35,"audienceRelevance":50,"eventTypeSecondary":["board_change"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"executive and board changes","sectorWeight":"Health Care","householdBrandBoost":"Cambridge-based biotech with strong industry credentials"}},"event_type":"executive_change","event_type_secondary":["board_change"],"sentiment":"bullish","material_impact_score":3,"narrative":"4basebio has appointed Richard Bungay as Chief Financial Officer, effective July 2026. Richard brings over 30 years of senior finance and strategic experience, including leading significant fundraising and M&A activities.\n\nNon-executive Directors Alexander Link and Alan Malus have stepped down from the Board due to other professional commitments, effective May 31, 2026. Dr. Heikki Lanckriet will take over Mr. Link’s role, and Mr. Cornel Chiriac is expected to replace Mr. Malus, pending due diligence and regulatory approval.\n\nCEO Amy Walker expressed enthusiasm about Richard’s appointment, noting his strategic and financial expertise will be invaluable as the company transitions into a phase of accelerated commercial growth.","key_figures":{"customDimensions":{"funding_raised":"$400m","in_licensing_deal_value":"$670m"}},"named_entities":{"people":[{"name":"Richard Bungay","role":"CFO"},{"name":"David Roth","role":"former CFO"},{"name":"Alexander Link","role":"Non-executive Director"},{"name":"Alan Malus","role":"Non-executive Director"},{"name":"Heikki Lanckriet","role":"Non-executive Director"},{"name":"Cornel Chiriac","role":"future Non-executive Director"},{"name":"Amy Walker","role":"CEO"}],"products":[],"companies":[{"name":"4basebio PLC","ticker":"MREO"},{"name":"Sitala Bio Limited","relationship":"former employer"},{"name":"Fosun Pharma","relationship":"partner"},{"name":"Diurnal Group plc","relationship":"former employer"},{"name":"Neurocrine Biosciences, Inc.","ticker":"NBIX","relationship":"acquirer"},{"name":"Mereo Biopharma Group plc","ticker":"MREO","relationship":"former employer"},{"name":"Novartis","relationship":"partner"},{"name":"Verona Pharma","relationship":"former employer"},{"name":"Merck & Co","relationship":"acquirer"},{"name":"Celltech Group plc","relationship":"former employer"},{"name":"UCB","relationship":"acquirer"},{"name":"2invest AG","relationship":"shareholder"},{"name":"M&G","relationship":"shareholder"},{"name":"Cairn Financial Advisers LLP","relationship":"Nominated Adviser"},{"name":"Cavendish Capital Markets Limited","relationship":"Joint Broker"},{"name":"RBC Capital Markets","relationship":"Joint Broker"},{"name":"ICR Healthcare","relationship":"Media and Investor Relations"}],"dollarAmounts":[{"amount":"$400m","context":"funding raised by Richard Bungay at Diurnal Group plc"},{"amount":"$670m","context":"in-licensing deal value with Fosun Pharma at Sitala Bio Limited"}]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-14T06:03:41.420Z","global_importance":35,"audience_relevance":50,"importance_components":{"tickerTier":"small-cap","eventGravity":"executive and board changes","sectorWeight":"Health Care","householdBrandBoost":"Cambridge-based biotech with strong industry credentials"}},"durationMs":33387,"modelName":"george-droid-qwen-72b"}}